No abstract available
Plain language summary
This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.
MeSH terms
-
Antiviral Agents* / therapeutic use
-
COVID-19 Drug Treatment* / methods
-
COVID-19 Drug Treatment* / statistics & numerical data
-
COVID-19* / diagnosis
-
COVID-19* / epidemiology
-
COVID-19* / prevention & control
-
Drug Combinations
-
Drug Prescriptions / statistics & numerical data
-
Health Inequities
-
Humans
-
Lactams / therapeutic use
-
Leucine / therapeutic use
-
Nitriles / therapeutic use
-
Post-Acute COVID-19 Syndrome* / drug therapy
-
Post-Acute COVID-19 Syndrome* / epidemiology
-
Post-Acute COVID-19 Syndrome* / prevention & control
-
Proline / therapeutic use
-
Ritonavir / therapeutic use
-
Severity of Illness Index
Substances
-
nirmatrelvir and ritonavir drug combination
-
Drug Combinations
-
Antiviral Agents
-
Lactams
-
Leucine
-
Nitriles
-
Proline
-
Ritonavir